Education
About Us
Working with TipRanks
Follow Us
Sarepta Therapeutics (SRPT)
NASDAQ:SRPT
SRPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$10.42 - $144.22
Previous CloseN/A
Volume185.86K
Average Volume (3M)17.13M
Market Cap
$1.98B
Enterprise Value$2.38B
Total Cash (Recent Filing)$800.14M
Total Debt (Recent Filing)$1.35B
Price to Earnings (P/E)19.6
Beta0.69
Next Earnings
Oct 29, 2025EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.89
Shares Outstanding97,713,440
10 Day Avg. Volume12,070,865
30 Day Avg. Volume17,127,845
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue0.96
Enterprise Value/Gross Profit1.21
Enterprise Value/Ebitda54.06
Forecast
1Y Price Target
$23.88Price Target Upside17.64% Upside
Rating ConsensusHold
Number of Analyst Covering30
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRevenue of ~$611M, above Citi/FactSet’s ~$530M, driven by a Roche milestone on Japanese Elevidys approval, gains on strategic investments, and an income tax benefit.
Market PositionWith ELEVIDYS back in the ambulatory setting, no issues are expected meeting the <4x total net leverage ratio required to draw upon the $600M revolver.
Product DemandThere is still enthusiasm amongst ambulatory patients to be dosed with Elevidys, with observed improvement and long-term stabilization of function.
Bears Say
Financial StrategyThe rapid pivot from strategic investment to divestiture in less than 12 months weakens Sarepta's credibility in capital allocation and renews concerns that Sarepta’s late-stage and commercial portfolio may not generate sufficient near-term cash to support its current debt and pipeline ambitions.
Regulatory ChallengesA recommendation for rejection of EU approval in ambulatory DMD patients, with the Committee for Medicinal Products for Human Use (CHMP) citing no statistical significance in NSAA.
Safety ConcernsElevidys’ risk profile on severe and possibly fatal liver-toxicity is unchanged, a persistent risk for investors.
Sarepta Therapeutics News
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $10.41 and its highest was $144.22 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $1.98B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Oct 29, 2025 which is in 74 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Aug 06, 2025. The company reported $1.89 earnings per share for the quarter, beating the consensus estimate of $0.832 by $1.058.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is -0.56.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 97,713,440 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of $1.89 in its last earnings report, beating expectations of $0.832. Following the earnings report the stock price went up 10.455%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
Sarepta Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$23.88 (17.64% Upside)
$23.88 (17.64% Upside)
Blogger Sentiment
Neutral
SRPT Sentiment 57%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 785.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.0%
Last 30 Days ▲ 8.5%
Last 30 Days ▲ 8.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.74%
12-Months-Change
Fundamentals
Return on Equity
-4.76%
Trailing 12-Months
Asset Growth
7.46%
Trailing 12-Months
Company Description
Sarepta Therapeutics
Sarepta Therapeutics (SRPT) is a biopharmaceutical company focused on developing innovative therapies for rare diseases, primarily targeting genetic disorders such as Duchenne muscular dystrophy (DMD). The company operates in the biotechnology sector and is known for its pioneering work in gene therapy and RNA-targeted medicines. Sarepta's lead product candidates include exon-skipping therapies and gene replacement therapies designed to address the underlying causes of DMD and other genetic conditions.
SRPT Company Deck
SRPT Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth and strong demand projections for the future. However, challenges such as the tragic patient safety incident, administrative delays, and site capacity imbalances have led to a downward revision of revenue guidance. Despite these challenges, the company remains optimistic about long-term demand and continues to work on addressing the issues.View all SRPT earnings summariesSRPT Stock 12 Month Forecast
Average Price Target
$23.88
▲(17.64% Upside)
Technical Analysis
Ownership Overview
4.14% Insiders
22.82% Mutual Funds
6.19% Other Institutional Investors
43.46% Public Companies and Individual Investors